Thorax

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
[Advanced]

Thorax. Published Online First: 5 December 2007. doi:10.1136/thx.2007.086751
Copyright © 2007 BMJ Publishing Group Ltd & British Thoracic Society

This Article
Right arrow Full Text (Rapid PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Sapey, E.
Right arrow Articles by Stockley, R. A
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sapey, E.
Right arrow Articles by Stockley, R. A

Papers

Inter-relationships between inflammatory markers in stable COPD patients with bronchitis: the intra and inter patient variability

Elizabeth Sapey 1, Darren Bayley 1, Ali Ahmad 2, Paul Newbold 3, Noel Snell 3 and Robert A Stockley 1*

1 University Hospital Birmingham NHS Foundation Trust, United Kingdom
2 University of Birmingham, United Kingdom
3 AstraZeneca R&D Charnwood, United Kingdom

* To whom correspondence should be addressed. E-mail: r.a.stockley{at}bham.ac.uk.

Accepted 2 November 2007


*   Abstract

Rationale: Measurements of pulmonary biomarkers can be used to monitor airway inflammation in COPD but the variability of sampled biomarkers and their inter relationships are poorly understood.

Objectives: to describe the intra and inter-patient variability in spontaneous sputum samples from patients in the stable state and to describe the relationships between biomarkers, cell counts and markers of disease.

Methods: Sputum Interleukin-1beta, Tumour necrosis factor alpha, Interleukin 8, Myeloperoxidase, Leukotriene B4, Growth related oncogene alpha and differential cell counts were measured in patients with moderate to severe stable COPD (n = 14) on 11 occasions over one month.

Measurements and main results: There was significant variability in all inflammatory indices (median intra-patient coefficient of variation (CV) = 35% (IQR 22 - 69), median inter-patient CV = 102% (IQR 61 - 145)). Variability could be reduced by using a rolling mean of individual patient data points. Sample size calculations were undertaken to determine the number of patients required to detect a 50% reduction in neutrophil count. Utilising a cross-over design of a putative effective therapy, the number needed using one data point per patient was 72, reducing to 23 when the mean of 3 data points was used.

Significant correlations were demonstrated both between the inflammatory biomarkers themselves and between inflammatory biomarkers and markers of disease. Some relationships were not apparent when results from a single sample were used. The reliability of inter-relationships improved as more data points were used for each patient.

Conclusions: Clear relationships exist between inflammatory biomarkers in stable COPD patients. Sequential sampling reduced the variability of individual mediators and the potential number of patients needed to power proof of concept interventional studies.


Keywords: COPD, Lung disease, Obstructive, Spontaneous sputum, Sputum biomarkers







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2007 BMJ Publishing Group Ltd & British Thoracic Society